Current treatment options and considerations in nmCRPC
On behalf of the Scientific Committee and the Scandinavian Bayer Oncology team we welcome you to attend this virtual meeting on the topic;
Current treatment options and considerations in nmCRPC
Tuesday, 18 May 2021 at 17:00–19:00
In the recent years new treatment modalities have been introduced that significantly improve outcomes for men with advanced CRPC. Active treatment is now available already in the non-metastatic stage (nmCRPC) using androgen receptor inhibitors (ARIs) in patients that are most often asymptomatic from their disease. This meeting is intended to share knowledge and discuss current trial data and clinically relevant treatment considerations in the management of these patients. Presentations are planned to allow time for discussions after each session.
